Another Phase I trial (NCT00931931) is evaluating HSV1716 delivered intratumorally or intravenously in adolescents and young adults with refractory non-CNS solid tumors, including NF1-associated MPNST, with primary safety and DLT assessment and extended immune-monitoring planned for long-term follow-up. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.